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Abstract
Introduction
The challenges in identifying a cohort of people with a rare condition can be addressed by routinely
collected, population-scale electronic health record (EHR) data, which provide large volumes of data
at a national level. This paper describes the challenges of accurately identifying a cohort of children
with Cystic Fibrosis (CF) using EHR and their validation against the UK CF Registry.
Objectives
To establish a proof of principle and provide insight into the merits of linked data in CF research; to
identify the benefits of access to multiple data sources, in particular the UK CF Registry data, and
to demonstrate the opportunity it represents as a resource for future CF research.
Methods
Three EHR data sources were used to identify children with CF born in Wales between 1st January
1998 and 31st August 2015 within the Secure Anonymised Information Linkage (SAIL) Databank.
The UK CF Registry was later acquired by SAIL and linked to the EHR cohort to validate the cases
and explore the reasons for misclassifications.
Results
We identified 352 children with CF in the three EHR data sources. This was greater than expected
based on historical incidence rates in Wales. Subsequent validation using the UK CF Registry found
that 257 (73%) of these were true cases. Approximately 98.7% (156/158) of individuals identified
as CF cases in all three EHR data sources were confirmed as true cases; but this was only the case
for 19.8% (20/101) of all those identified in just a single data source.
Conclusion
Identifying health conditions in EHR data can be challenging, so data quality assurance and validation
is important or the merit of the research is undermined. This retrospective review identifies some of
the challenges in identifying CF cases and demonstrates the benefits of linking cases across multiple
data sources to improve quality.
Introduction
There is increasing interest in using routinely collected,
population-scale, electronic health record (EHR) administra-
tive data, in order to conduct research. At population level
these data sources can provide large volumes of data and a
broad longitudinal view of a condition over a period of time
[1-3]. In Wales, the Secure Anonymised Information Linkage
(SAIL) Databank is the national repository of anonymised,
person based, linkable data [4,5]. It holds routine EHR data
from primary and secondary health care for about 5 million
people from the turn of the century, including the active pop-
ulation of about 3.1 million people. Earlier data are available
but at lower quality.
SAIL data are held within the privacy protecting UK Secure
Research Platform (UKSeRP) based at Swansea University [6].
The SAIL Databank has a strict set of policies, structures and
control practices in place to protect privacy through a match-
ing, anonymisation and encryption process. The anonymisa-
tion process is conducted by the NHS Wales Informatics Ser-
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vice (NWIS) and involves splitting any identifiable data from
the clinical data and assigning an Anonymised Linkage Field
(ALF) to an individual based on a number of matching cri-
teria. This enables the linkage of cases across multiple data
sources that are acquired and linked into SAIL through match-
ing via their ALF, and allows a broad longitudinal view of their
conditions and treatments [7,8] .
Whilst there is considerable value to be gained from the
use of routine EHR for research, it also poses a number of
challenges [9-12]. These can occur because routine EHR rely
on data collected for administrative purposes rather than clin-
ical research, so identifying clinical outcomes or decisions can
be more difficult. In addition, the coding systems used in the
data may not be able to accurately convey the diagnostic con-
ditions of interest. Accordingly, effective methodologies are
required to both extract and validate these data to achieve
high data quality and enable their use in clinical research [13].
In this study, we make use of a cohort of children with
cystic fibrosis (CF) in Wales identified from electronic health
records in SAIL from a previous study [14]. CF is a life-limiting,
genetic disease caused by variants of the CF trans-membrane
conductance regulator (CFTR) gene. It is characterised by
the dysregulation of water and chloride ion transport across
epithelial cell membranes leading to the build-up of mucus in
various organs, in particular, those of the respiratory and diges-
tive systems. CF is a classically inherited autosomal recessive
condition whereby two faulty copies of the gene are necessary
to develop CF. The severity of the disease can vary greatly and
depends on a wide range of factors including the combination
of mutations that someone inherits [15,16]. People with one
faulty copy of the CFTR gene are carriers but do not display
any symptoms. Approximately 1 in 2,500 babies born in the
UK each year have CF [17] with 12 to 14 children with CF
born in Wales every year [18].
CF is a rare condition and as with many rare diseases, ac-
cess to enough cases for research can be problematic in the
absence of access to national disease registries or where out-
comes of interests are not captured in the registries [19]. We
describe the challenges of accurately identifying children with
CF in EHR and their validation against the UK CF Registry.
We aim to establish a proof of principle and provide insight
into the merits of linked data in CF research and the benefits
of access to multiple data sources. In particular we highlight
the benefit of linkage of routine data to the UK CF Registry
and demonstrate the opportunity it represents as a resource
for future CF research.
Methods
This paper has been produced based on guidelines recom-
mended for observational studies using administrative data
[21-22].
Data Sources
Several independent health data sources were available in the
SAIL Databank in which it was possible to identify children
with a CF diagnosis code. The Welsh Longitudinal Gen-
eral Practice (WLGP) data contains records of primary care
General Practitioner (GP) events for people registered with
a Welsh GP who contributes data to SAIL. Currently there
is approximately 80% coverage of these data and the release
made available to our study covered events from 1970 up to
2016. The Patient Episode Database for Wales (PEDW) data
contains records of secondary care hospital admissions for all
episodes of in-patient care, attending as a day-case or a longer
term in-patient admission, in any NHS hospital. It also holds
details for each episode of care, including diagnoses and treat-
ment procedures. The release made available to our study
covered admissions from 2000 to 2016.
The Congenital Anomaly Register Information Service
(CARIS) data contains records of specialist registry data with
details of babies and foetuses resident in Wales at time of
birth, for whom an anomaly has been detected during preg-
nancy, birth or during the first year of life. Some of these
anomalies, including CF, are picked up via a new-born screen-
ing test in the first week of birth, which was introduced in
Wales in 1996 [23,24]. The release made available to our
study covered children born from 1997 to 2013.
Furthermore, in order to identify children resident in Wales
and extract and check background details, it was necessary to
use other complementary data sources. These included the
Welsh Demographic Service Dataset (WDSD), the National
Community Child Health (NCCH) data, the Annual District
Birth Extract (ADBE) data and the Annual District Death
Extract (ADDE) data. For a description of these complemen-
tary data sources please see Supplementary Appendix 1.
The UK CF Registry records health data on consenting
people with CF in England, Northern Ireland, Scotland and
Wales and is managed by the Cystic Fibrosis Trust [25]. The
data held by the Registry are collected at annual review vis-
its at specialist CF care centres across the UK dating back
to 1996. The data include a wide range of outcomes, com-
plications and treatments, enabling research on a variety of
issues in CF. It is estimated that the UK CF Registry captures
99% of the UK CF population [17]. The UK CF Registry was
not available in the SAIL Databank at the time the initial CF
cohort was derived [14]. However, at the end of 2018, the Cys-
tic Fibrosis Trust gave permission for their data to be used in
the SAIL Databank. The release made available to our study
covered births to early 2018.
Method used to identify children in Wales with
CF in the routine EHRs
Two different coding systems were required to identify people
with CF in the EHR. The International Classification of Dis-
eases Version 10 (ICD 10) is used to record diseases in PEDW
and CARIS, whilst Read code Version 2 is used in WLGP. The
list of ICD-10 and Read codes used to identify CF can be
found in Supplementary Appendix 2. Structured Query Lan-
guage (SQL) was adopted to extract all the data relating to
the CF children.
In order to identify children resident in Wales, born be-
tween 1998 and 2015, an initial cohort of just under 600,000
children was extracted from the WDSD. This cohort was used
as the basis for identifying those children in the WLGP, PEDW
and CARIS data sources with a CF diagnosis code. This re-
sulted in three independent groups of CF cases – one for each
data source used to identify CF cases. The three groups were
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then cross matched and linked via their unique ALF and the
data source of the diagnosis flagged.
Linkage with the UK CF Registry
At the end of 2018, the UK CF Registry was acquired into the
SAIL Databank. Data acquisition by SAIL involves the nego-
tiation and agreement of data owners and providers agreeing
the use of their data in an anonymised format, for the use
in research for the public good. Data that are acquired are
then appropriately handled and managed through a split file
process, that ensures identifiers and clinical information are
handled and linked safely and securely [2,5,7].
Records from the three EHR data sources could then be
linked to the cases in the UK CF Registry via their ALF. The
availability of this ‘gold-standard’ in SAIL, now provided the
opportunity to validate the original EHR cohort and identify
the true cases. To this end, children born between January
1998 and August 2015 were identified within the UK CF reg-
istry and matched to our EHR cohort. In addition, it also pro-
vided an opportunity to identify Welsh resident children with
CF that may have been unidentified previously. To determine
Welsh residency in the UK CF Registry, we used LSOA (Lower
layer Super Output Area) codes. LSOA is a geographic hierar-
chy level for statistical reporting and the highest granularity of
identifiable geography permitted within the SAIL Databank in
order to preserve privacy protection. In the 2001 Census list-
ing there are 1,896 LSOAs in Wales, each with a population
of about 1,500 people [26]. LSOA information is recorded for
cases within the UK CF Registry. We report the positive pre-
dictive value of our method to identify CF cases in EHR. 95%
confidence interval is based on the Gaussian approximation.
Results
Identification of children with CF in Wales us-
ing EHR
Using ICD-10 and Read codes in the three data sources the
following numbers of cases were found: 252 in CARIS, 265 in
PEDW and 244 in WLGP (see Figure 1).
After matching the children on unique ALFs across all three
data sources, we found a total of 352 unique children with CF
diagnostic codes born between January 1998 and August 2015.
This was higher than expected, given the incidence of CF in
Wales, and it was assumed that some cases had been misclas-
sified. As CF is a serious condition, often picked up at birth
and likely to prompt frequent visits to a GP and possibly hos-
pital admissions, there was an expectation that any child with
CF would have records in multiple data sources, and the most
likely true cases would be those with records in all three data
sources.
Validation of the EHR cohort against cases
held within the UK CF Registry
Linkage of the 352 EHR cases with the UK CF Registry found
257 matched cases indicating that 95 cases identified in the
EHR (27%) were potential false positives. Our method for
identifying CF cases therefore had a positive predictive value
of 0.73 (95% CI 0.68 – 0.78). Furthermore, 235 children were
found with Welsh LSOA codes in the UK CF Registry, and
with the exception of 11, all had been already identified in the
EHR cohort.
Figure 1 illustrates the numbers of cases extracted from
the respective data sources, and the numbers of cases that
matched between the EHR and UK CF Registry data sources.
Approximately 99% (156/158) of EHR cases, with records
in all three data sources, could be matched to individuals in the
UK CF Registry. This supported our assumption that cases in
this group would be the least likely to be misclassified. How-
ever, this group only captured 60% of the children we could
match to the UK CF Registry. For individuals identified across
two data sources, 87% (81/93) could be matched; these made
up 32% (81/257) of all the children matched to the UK CF
Registry. All individuals identified in CARIS and WLGP could
be found in the Registry. Out of the individuals identified in
CARIS and PEDW or PEDW and WLGP, 84% (42/50) and
89% (34/38) could be found in the Registry, respectively. Only
19.8% (20/101) of EHR cases, for whom we found a CF diag-
nosis code in just a single data source could be found in the
UK CF Registry. The lowest proportion of true positives was
in the group identified in CARIS (12.8% ( 5/39)) , followed by
those identified in WLGP (13.9% ( 6/43) ); amongst children
with a CF code only in PEDW 47% (9/47) could be matched
(Figure 2 ).
Examination of the 95 false positive EHR
cases
As the UK CF Registry captures 99% of the UK CF popula-
tion [17], we suspect that most of the 95 cases identified in
the EHR which were not found in the UK CF Registry were
false positives. Within the group of children identified in two
EHR sources but not found in the UK CF Registry, six children
died during the study period, most within the first few years of
life. In the group of cases found in both WLGP and PEDW,
there was some evidence that what was being flagged was a
‘suspicion of’, or an’ investigation into CF’ rather than a diag-
nosis. In the group of cases found in CARIS and PEDW, some
children (< 5) had a number of comorbidities. All the children
identified in both CARIS and WLGP data sources were found
in the UK CF Registry.
A little over 80% of all children found only in single data
sources, were suspected to be wrongly identified with CF, and
the predominant reason for misclassification appeared to be
that CF was suspected but never confirmed in these children.
The cases misclassified in CARIS had additional information
within the records suggesting that a number of the children
had been flagged as ‘carriers of CF’, having a ‘suspicion of
CF’ or having ‘borderline sweat tests’. A small number (<5)
of these children had also died and had complex congenital
abnormalities. Cases misclassified in PEDW only, included
children who also had complex health problems.
The biggest group of misclassified cases were found in the
WLGP dataset. 14 were flagged as having been ‘seen in the CF
clinic’ but had no further CF related records. Primary Prac-
tice is where most preliminary investigations for CF would take
place and the most likely place for a new case, suspected or
otherwise to be flagged up and recorded. Although there are
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Figure 1: Illustration of the number of children with cystic fibrosis (CF) identified in electronic health records (EHR) in Wales, the
number children in the UK CF Registry and the number of cases matched between the EHR cohort and the Registry. Sources used
for identification of CF cases in EHR were Patient Episode Database for Wales (PEDW), Congenital Anomaly Register Information
Service (CARIS) and Welsh Longitudinal General Practice (GP).
Read codes for ‘suspected CF’, a simple CF diagnosis code
seemed to be used in preference.
Examination of the eleven missing cases
The 11 children not identified in the EHR, were not found in
any of the three datasets, with or without a CF diagnosis code.
As they were not in CARIS, this implies they were not born in
Wales and were not part of the Welsh new-born screening pro-
gramme. The children may have moved into Wales at some
date after the EHR cohort had been created.
Discussion
We identified a cohort of children with Cystic Fibrosis (CF)
in routinely collected data and validated these against a co-
hort of true cases. We showed that we could correctly identify
95% (224/235) of the true Welsh CF cases in electronic health
records, however we had a high number of false positives (27%
of the identified population). Our results highlighted that us-
ing multiple data sources is helpful in reducing the misclas-
sification problem, and is particularly beneficial when a gold
standard dataset is not available.
EHR data are of great benefit to research, but these data
sources demand a good clinical understanding of the condi-
tion of interest and a good understanding of their administra-
tive purposes. This includes how the data are collected, how
they are used and coded for particular conditions and how
frequently they are updated. There is an increasing acknowl-
edgement that multiple record linkage , when used to combine
information from a variety of digital health sources, is a power-
ful mechanism, and can generate rich comprehensive research
data [27]. In this case, access to the routine health records in
primary and secondary care, the data collected on congenital
anomalies and the supplementary data collected in other sup-
porting administrative data sources, were all available. Col-
lectively, these were able to provide detailed information on
disease conditions and treatments and the timings of events
such as general interactions with services and provisions of
care, potentially outside the main focus of CF treatment but
affecting ongoing health.
There is an increasing interest in understanding health,
social and economic consequences of CF beyond what is cap-
tured in the registries. This is highlighted by the increasing
number of studies linking EHR to other CF Registries , for ex-
ample to study the economic impact of CF [28] or to address
detailed questions relating to in-hospital care of people with
CF [29]. In this study, we have shown the importance of using
multiple data sources to identify individuals with CF if a gold
standard (e.g. a CF Registry) is not available. Using only
one data source, for example hospital admissions data, will
underestimate the number of cases and may bias the analy-
ses. Although our method overestimated the number of CF
children, the method managed to capture all but eleven of
them, and showed good quality when using them in combina-
tion. The final validation of the cohort using a gold-standard
demonstrated that the majority of cases identified in all three
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Figure 2: This diagram shows the number of children with CF codes in CARIS, PEDW and WLGP and the percentage of children
matched to the UK CF Registry data. The table at the bottom of the figure gives the total number of cases identified in each
EHR data source and the percentage of children found in the UK CF Registry.
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data sources, were also found in the UK CF Registry, thus
confirming our assumption that multiple data sources can help
improve the accurate identification of cases. Based on these
results, we would recommend that any study of CF using EHR
data without a gold standard, considers a range of sensitivity
analyses which use case definitions based on the identification
of cases in different combinations of data sources.
Identifying missing cases, such as the eleven not identi-
fied in the original EHR, can be a challenge. This occurred in
our study when extracting and matching records from multiple
data sources which were updated at different times and cov-
ered different time periods. For the small number of missing
cases, a further investigation showed that CF records could be
found for some, but only in much later versions of the health
data and none appeared to be living in Wales at the time the
EHR cohort was extracted. The SAIL Databank receives reg-
ular updated extracts of routine EHR data, and there is an
agreement to receive further UK CF Registry updates in the
future. Using the established coding classifications and the re-
producible methods we have developed to identify and validate
the CF cases, we can now maintain and update this derived
CF EHR cohort for future research purposes.
Finally, for a condition like CF, there is an additional chal-
lenge when there is a need to record ‘suspected’ and ‘bor-
derline’ cases, using the ICD-10 coding system, as it does
not have a specific code to record either of these conditions.
There are ICD-10 codes for identifying screening for genetic
carriers and genetic susceptibility for disease, but these were
not used for the EHR CF cohort and so ‘E84’ was used as a
proxy. The Read codes seemed to suggest the opposite prob-
lem; there are a large number of codes for recording a CF
condition, suspected or otherwise but given the wide choice, a
simple CF diagnosis code was often chosen. The use of coding
systems in a consistent manner and the limitations apparent
in some coding systems, is a recognised concern in the use of
EHR [10,30] and the reasons for the misclassified cases seemed
consistent with this concern.
Conclusion
Linked population level EHR offered a valuable resource for
this research and the SAIL Databank provided a secure envi-
ronment in which it was possible to link cases across multiple
data sources. Although linking data in this manner can help
reduce the risk of misclassification, access to a gold-standard
will always be advantageous, as it will permit the verification
of the true cases.
For future CF research, this also demonstrates the ability
to link the UK CF Registry data to a derived EHR cohort, pro-
viding a more enriched set of data for analysis of the condition,
which can now be maintained and updated using these estab-
lished coding classifications and reproducible methods. These
can also be used to identify and validate future CF cases, of-
fering a complementary resource to the annual review data
already collected by the UK CF Registry.
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Supplementary Appendices
Supplementary Appendix 1
Complementary Data Sources.
These datasets provided background details on the CF cases
and assisted in the validation of the data extracted for the
cohort:
The Welsh Demographic Service Dataset (WDSD) com-
plements the WLGP events data and maintains longitudi-
nal records of GP registrations and residence changes across
Wales. It also records Welsh residents’ demographic details
such as week of birth, gender and date of death where appli-
cable. This was the means by which children resident in Wales
were identified. This release covered births up to 2015.
The National Community Child Health data (NCCH): Each
of the seven health boards in Wales collect records on mater-
nal and child health, born, resident or treated in Wales after
1987. It includes a range of data items including birth details
such as week of birth, gestational age, gender, multiple birth
and breastfeeding indicators and enables a child to be linked
to their mother (31). This release covered children born from
1997 to early 2016.
The Annual District Birth Extract (ADBE) and the Annual
District Death Extract (ADDE). These records are provided by
the Office of National Statistics (ONS), and contain details on
week of birth and birth weight, and date of death, and cause
of death respectively. This release covered the period up to
2015.
Supplementary Appendix 2
ICD10 and Read codes
ICD10 codes used to identify CF in CARIS and PEDW data.
CF ICD 10 codes Description
E84 Cystic fibrosis
E840 Cystic fibrosis with pulmonary
manifestations
E841 Cystic fibrosis with intestinal man-
ifestations
E488 Cystic fibrosis with other manifes-
tations
E849 Cystic fibrosis, unspecified
Read codes used to identify CF in GP data.
CF Read Code Description
1264. FH: Cystic fibrosis
66k.. Cystic fibrosis monitoring
66k0. Cystic fibrosis annual review
9No7. Seen in cystic fibrosis clinic
C370. Cystic fibrosis
C3701 Meconium ileus in cystic fibrosis
C3702 Cystic fibrosis with pulmonary
manifestations
C3703 Cystic fibrosis with intestinal man-
ifestations
C3704 Arthropathy in cystic fibrosis
C3707 Liver dis due cystic fibrosis
C3709 Exacerbation cystic fibrosis
C370y Cystic fibrosis other manifest
C370z Cystic fibrosis NOS
References
1. McGrail K, Jones K, Akbari A, Bennett T, Boyd A, Car-
inci F, et al. A Position Statement on Population Data
Science: The science of data about people. Int J Popul
Data Sci [Internet]. 2018;3(1):1–11. Available from:
https://doi.org/10.23889/ijpds.v3i1.415
2. Jones KH, Ford DV, Jones C, Dsilva R, Thompson S,
Brooks CJ, et al. A case study of the secure anony-
mous information linkage (SAIL) gateway: A privacy-
protecting remote access system for health-related re-
search and evaluation. J Biomed Inform [Internet].
2014;50:196–204. Available from: https://doi.org/
10.1016/j.jbi.2014.01.003
3. Virnig BA, Mcbean M. Administrative Data for Public
Health Surveillance and Planning [Internet]. Vol. 22,
Annu. Rev. Public Health. 2001 [cited 2019 May
13]. Available from: https://doi.org/10.1146/
annurev.publhealth.22.1.213
4. Lyons RA, Jones KH, John G, Brooks CJ, Verplancke
JP, Ford D V., et al. The SAIL databank: Linking
multiple health and social care datasets. BMC Med
Inform Decis Mak. 2009;9(1):1–8. Available from:
https://doi.org/10.1186/1472-6947-9-3
5. Bodger O, Lyons RA, Jones KH, Couch T, Brown
G, Verplancke J-P, et al. The SAIL Databank:
building a national architecture for e-health re-
search and evaluation. BMC Health Serv Res.
2009;9(1):1–12.Available from: https://doi.org/
10.1186/1472-6963-9-157
6. UK Secure eResearch Platform -SAIL databank [Inter-
net]. [cited 2019 Aug 13]. Available from: https://
saildatabank.com/wp-content/uploads/UKSeRP_
Brochure_v1.5.pdf
7. Jones KH, Ford DV, Thompson S, Lyons R. A Profile
of the SAIL Databank on the UK Secure Research Plat-
form. Int J Popul Data Sci [Internet]. 2019;4(2). Avail-
able from: https://ijpds.org/article/view/1134
and https://doi.org/10.23889/ijpds.v4i2.1134
7
Griffiths, R et al. / International Journal of Population Data Science (2020) 5:1:24
8. Sibthorpe B, Kliewer E, Smith L. Record linkage in Aus-
tralian epidemiological research: health benefits, pri-
vacy safeguards and future potential. Aust J Pub-
lic Health [Internet]. 2010 Feb 12 [cited 2019 May
13];19(3):250–6. Available from: http://doi.wiley.
com/10.1111/j.1753-6405.1995.tb00439.x
9. Wing K, Bhaskaran K, Smeeth L, Van Staa TP, Klun-
gel OH, Reynolds RF, et al. Optimising case detec-
tion within UK electronic health records: use of multiple
linked databases for detecting liver injury. [cited 2019
Apr 8]; Available from: https://doi.org/10.1136/
bmjopen-2016-012102
10. Tsopra R, Peckham D, Beirne P, Rodger K, Callister M,
White H, et al. The impact of three discharge coding
methods on the accuracy of diagnostic coding and hospi-
tal reimbursement for inpatient medical care. Int J Med
Inform [Internet]. 2018;115(July 2017):35–42. Avail-
able from: https://doi.org/10.1016/j.ijmedinf.
2018.03.015
11. Nouraei SAR, O’Hanlon S, Butler CR, Hadovsky A,
Donald E, Benjamin E, et al. A multidisciplinary au-
dit of clinical coding accuracy in otolaryngology: Fi-
nancial, managerial and clinical governance consider-
ations under payment-by-results. Clin Otolaryngol.
2009;34(1):43–51. Available from: https://doi.org/
10.1111/j.1749-4486.2008.01863.x
12. Raftery J, Roderick P, Stevens A. Potential use of rou-
tine databases in health technology assessment. Health
Technol Assess (Rockv). 2005;9(20). Available from:
https://doi.org/10.3310/hta9200
13. Stuart G. Nicholls PhD, Sinéad M. Langan MSc PhD
EIBMP. Routinely collected data: the importance of
high-quality diagnostic coding to research. C 2017 Au-
gust 21 [Internet]. 2017 [cited 2019 Dec 20]; Available
from: https://doi.org/10.1503/cmaj.170807
14. Schlüter DK, Griffiths R, Adam A, Akbari A, Heaven
ML, Paranjothy S, et al. Impact of cystic fi-
brosis on birthweight: A population based study
of children in Denmark and Wales. Thorax.
2018;1–8. Available from : https://doi.org/10.
1136/thoraxjnl-2018-211706
15. Spicuzza L, Sciuto C, Dio L Di, Mattina T, Leonardi
S, Miraglia Del Giudice M, et al. Mild cystic fibrosis in
patients with the rare P5L CFTR mutation. 2012 [cited
2019 May 13]; Available from: https://doi.org/10.
1016/j.jcf.2011.08.009
16. De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani
L. The relative frequency of CFTR mutation classes in
European patients with cystic fibrosis. J Cyst Fibros [In-
ternet]. 2014 Jul 1 [cited 2019 May 13];13(4):403–9.
Available from: https://doi.org/10.1016/j.jcf.
2013.12.003
17. Taylor-Robinson D, Archangelidi O, Carr SB, Cosgriff R,
Gunn E, Keogh RH, et al. Data resource profile: The
UK cystic fibrosis registry. Int J Epidemiol. 2018 Feb
1;47(1):9-10e. Available from : https://doi.org/10.
1093/ije/dyx196
18. (CARIS) CAR and IS. Congenital Anomaly Register
and Information Service (CARIS) - Metabolic & En-
docrine [Internet]. Congenital Anomaly Register and
Information Service (CARIS); [cited 2019 May 13].
Available from: http://www.caris.wales.nhs.uk/
metabolic#CysticFibrosis
19. Schieppati A, Henter JI, Daina E, Aperia A. Why rare
diseases are an important medical and social issue. The
Lancet. 2008. Available from: https://doi.org/10.
1016/S0140-6736(08)60872-7
20. Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher
D, et al. The REporting of studies Conducted using Ob-
servational Routinely-collected health Data (RECORD)
Statement. PLoS Med [Internet]. 2015 [cited 2019 Apr
9];6(10):1001885. Available from: https://doi.org/
10.1371/journal.pmed.1001885
21. Chen MY, Langan S, Benchimol EI. Routinely collected
electronic health data and STI research: RECORD ex-
tension to the STROBE guidelines. Sex Transm In-
fect. 2016;92(1):2–3. Available from:https://doi.
org/10.1136/sextrans-2015-052360
22. Boyd JH, Randall SM, Ferrante AM, Bauer JK, McIn-
neny K, Brown AP, et al. Accuracy and complete-
ness of patient pathways – the benefits of national data
linkage in Australia. BMC Health Serv Res [Internet].
2015 Dec 8 [cited 2019 May 13];15(1):312. Avail-
able from: https://doi.org/10.1186/s12913-015-0981-
2 http://bmchealthservres.biomedcentral.com/
articles/10.1186/s12913-015-0981-2
23. Doull IJM, Hall SJ, Bradley DM. A sweat test cen-
tered protocol for the disclosure and diagnosis of cys-
tic fibrosis in a newborn screening program. Pediatr
Pulmonol. 2007;42(9):773–8. Available from: https:
//doi.org/10.1002/ppul.20664
24. Doull IJM, Course C, Hanks R, Moat S. Newborn
Screening for Cystic Fibrosis in Wales over 20 years.
Changes in incidence dependent on screening protocol.
In: Cystic fibrosis [Internet]. European Respiratory So-
ciety; 2018 [cited 2019 May 13]. p. PA4628. Avail-
able from: http://erj.ersjournals.com/lookup/
doi/10.1183/13993003.congress-2018.PA4628
25. Cystic Fibrosis Trust [Internet]. www.cysticfibrosis.org.uk.
[cited 2019 Aug 1]. Available from: https://www.
cysticfibrosis.org.uk/what-is-cystic-fibrosis/
faqs#Howcommoniscysticfibrosis?
26. Welsh Index of Multiple Deprivation | GOV.WALES [In-
ternet]. [cited 2020 Jan 10]. Available from: https://
gov.wales/welsh-index-multiple-deprivation
27. Padmanabhan S, Carty L, Cameron E, Ghosh RE,
Williams R, Strongman H. Approach to record link-
age of primary care data from Clinical Practice Re-
search Datalink to other health-related patient data:
8
Griffiths, R et al. / International Journal of Population Data Science (2020) 5:1:24
overview and implications. Eur J Epidemiol [Internet].
2019;34(1):91–9. Available from: https://doi.org/
10.1007/s10654-018-0442-4
28. Jiao T, Biskupiak JE, Ye X, Unni S, Dowd
C, Fink A, et al. Development Of A Linked
Database For Cystic Fibrosis Research By Integrat-
ing A Patient Registry With Administrative Claims
Data. Value Heal. 2016;19(3):A81. Available
from: https://www.valueinhealthjournal.com/
article/S1098-3015(16)01835-0/pdf
29. Cogen JD, Hall M, Loeffler DR, Gove N, Onchiri F, Saw-
icki GS, et al. Linkage of the CF foundation patient
registry with the pediatric health information system
database. Pediatr Pulmonol. 2019;54(6):721–8. Avail-
able from: https://doi.org/10.1002/ppul.24272
30. Tsopra R, Wyatt JC, Beirne P, Rodger K, Callister M,
Ghosh D, et al. Level of accuracy of diagnoses recorded
in discharge summaries: A cohort study in three respira-
tory wards. J Eval Clin Pract. 2019;25(1):36–43. Avail-
able from: https://doi.org/10.1111/jep.13020
31. Hyatt M, Rodgers SE, Paranjothy S, Fone D, Lyons RA.
The wales electronic cohort for children (WECC) study.
Arch Dis Child - Fetal Neonatal Ed [Internet]. 2011 Jun
1;96(Suppl 1):Fa18 LP-Fa18. Available from: https:
//doi.org/10.1136/archdischild.2011.300164.6
9
